Autolus Therapeutics plc (AUTL) Shareholder Equity
- 2026-06-30: Additional Paid in CapitalUSD $1.58B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-6.10M; Retained Earnings (Accumulated Deficit)USD $-1.50B; Stockholders' Equity Attributable to ParentUSD $74.84M.
- 2026-03-31: Additional Paid in CapitalUSD $1.57B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-6.63M; Retained Earnings (Accumulated Deficit)USD $-1.46B; Stockholders' Equity Attributable to ParentUSD $108.83M.
- 2025-12-31: Additional Paid in CapitalUSD $1.57B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-5.36M; Retained Earnings (Accumulated Deficit)USD $-1.39B; Stockholders' Equity Attributable to ParentUSD $178.13M.
- 2025-09-30: Additional Paid in CapitalUSD $1.57B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-4.92M; Retained Earnings (Accumulated Deficit)USD $-1.30B; Stockholders' Equity Attributable to ParentUSD $265.45M.
Autolus Therapeutics plc Shareholder Equity
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Additional Paid in Capital USD | Accumulated Other Comprehensive Income (Loss), Net of Tax USD | Retained Earnings (Accumulated Deficit) USD | Stockholders' Equity Attributable to Parent USD | Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs USD | APIC, Share-based Payment Arrangement, Increase for Cost Recognition USD | Common Stock, Value, Issued USD | Adjustments to Additional Paid in Capital, Warrant Issued USD |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $1.58B | $-6.10M | $-1.50B | $74.84M | (m) | 3 month · $4.59M | (m) | (m) |
| 2026-03-31 | $1.57B | $-6.63M | $-1.46B | $108.83M | (m) | 3 month · $3.57M | (m) | (m) |
| 2025-12-31 | $1.57B | $-5.36M | $-1.39B | $178.13M | (m) | 12 month · $14.51M | (m) | (m) |
| 2025-09-30 | $1.57B | $-4.92M | $-1.30B | $265.45M | (m) | 3 month · $3.89M 9 month · $11.07M | (m) | (m) |
| 2025-06-30 | $1.56B | $862.00K | $-1.22B | $346.46M | (m) | 3 month · $4.30M | (m) | (m) |
| 2025-03-31 | $1.56B | $-18.11M | $-1.17B | $371.11M | (m) | 3 month · $2.88M | (m) | (m) |
| 2024-12-31 | $1.56B | $-29.17M | $-1.10B | $427.32M | 12 month · $29.36M | 12 month · $15.47M | (m) | (m) |
| 2024-09-30 | $1.55B | $-898.00K | $-1.07B | $476.96M | (m) | 3 month · $4.02M 9 month · $9.24M | (m) | (m) |
| 2024-06-30 | $1.55B | $-27.91M | $-989.52M | $527.84M | (m) | 3 month · $2.94M | (m) | (m) |
| 2024-03-31 | $1.54B | $-28.93M | $-931.25M | $582.03M | (m) | 3 month · $2.29M | (m) | (m) |
| 2023-12-31 | $1.02B | $-28.99M | $-878.56M | $111.47M | (m) | 12 month · $11.25M | (m) | (m) |
| 2023-09-30 | $1.02B | $-33.79M | $-801.39M | $180.52M | (m) | 3 month · $2.86M 9 month · $7.95M | (m) | (m) |
| 2023-06-30 | $1.01B | $-27.96M | $-755.54M | $229.34M | (m) | 3 month · $2.67M | (m) | (m) |
| 2023-03-31 | $1.01B | $-33.26M | $-709.99M | $266.92M | (m) | 3 month · $2.42M | (m) | (m) |
| 2022-12-31 | $1.01B | $-38.90M | $-670.18M | $298.67M | (m) | 12 month · $12.01M | (m) | (m) |
| 2022-09-30 | $851.82M | $-47.56M | $-643.23M | $161.15M | (m) | 3 month · $3.34M 9 month · $8.60M | (m) | (m) |
| 2022-06-30 | $848.37M | $-33.51M | $-600.46M | $214.52M | (m) | (m) | (m) | (m) |
| 2022-03-31 | $845.45M | $-16.02M | $-558.40M | $271.14M | (m) | (m) | (m) | (m) |
| 2021-12-31 | $843.11M | $-8.57M | $-521.34M | $313.32M | (m) | 12 month · $9.94M | (m) | 12 month · $9.87M |
| 2021-03-31 | $716.54M | $-4.59M | $-412.51M | $299.57M | (m) | (m) | (m) | (m) |
| 2020-12-31 | $595.02M | $-5.86M | $-379.24M | $210.03M | (m) | 12 month · $20.02M | (m) | (m) |
| 2020-09-30 | $590.37M | $-17.30M | $-336.38M | $236.81M | (m) | 3 month · $4.25M 9 month · $15.79M | (m) | (m) |
| 2020-06-30 | $586.11M | $-28.21M | $-299.07M | $258.95M | (m) | 3 month · $5.30M | (m) | (m) |
| 2020-03-31 | $580.77M | $-26.39M | $-267.02M | $287.48M | (m) | 3 month · $6.24M | (m) | (m) |
| 2019-12-31 | $500.56M | $-8.69M | $-237.15M | $254.84M | (m) | 12 month · $30.39M | (m) | (m) |
| 2019-09-30 | $494.08M | $-28.35M | $-196.21M | $269.64M | (m) | 3 month · $7.71M 9 month · $23.94M | (m) | (m) |
| 2019-06-30 | $486.37M | $-19.31M | $-168.96M | $298.22M | (m) | 3 month · $8.87M | (m) | (m) |
| 2019-03-31 | (m) | (m) | (m) | $217.88M | (m) | 3 month · $7.37M | (m) | (m) |
| 2018-12-31 | $361.31M | $-15.49M | $-113.30M | $232.64M | (m) | 3 month · $3.39M | (m) | (m) |
| 2018-09-30 | $357.92M | $-9.92M | $-92.65M | $255.47M | (m) | 3 month · $2.19M 9 month · $5.91M 12 month · $6.76M | (m) | (m) |
| 2018-06-30 | (m) | (m) | (m) | $267.11M | (m) | 3 month · $2.38M | (m) | (m) |
| 2018-03-31 | (m) | (m) | (m) | $127.10M | (m) | 3 month · $1.34M | (m) | (m) |
| 2017-12-31 | $195.64M | (m) | (m) | $137.51M | (m) | 15 month · $3.15M | $1.00K | (m) |
| 2017-09-30 | $194.35M | $-3.85M | $-47.90M | $142.60M | (m) | 12 month · $3.15M | (m) | (m) |
| 2016-09-30 | (m) | (m) | (m) | $30.69M | (m) | 12 month · $2.26M | (m) | (m) |
| 2015-09-30 | (m) | (m) | (m) | $10.50M | (m) | (m) | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 |